Candidiasis pipeline review, h1 2014

192 views

Published on

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
192
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Candidiasis pipeline review, h1 2014

  1. 1. Candidiasis - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Candidiasis The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Candidiasis Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 candidiasis Overview 10 therapeutics Development 11 pipeline Products For Candidiasis Overview 11 pipeline Products For Candidiasis Comparative Analysis 12 candidiasis Therapeutics Under Development By Companies 13 candidiasis Therapeutics Under Investigation By Universities/institutes 15 candidiasis Pipeline Products Glance 16 late Stage Products 16 clinical Stage Products 17 early Stage Products 18 unknown Stage Products 19 candidiasis Products Under Development By Companies 20 candidiasis Products Under Investigation By Universities/institutes 21 candidiasis Companies Involved In Therapeutics Development 22 sequella, Inc. 22 daiichi Sankyo Company, Limited 23 merck & Co., Inc. 24 novartis Ag 25 eisai Co., Ltd. 26 ico Therapeutics Inc. 27 almirall, S.a. 28 basilea Pharmaceutica Ag 29 pacgen Life Science Corporation 30 novadigm Therapeutics, Inc. 31 cellceutix Corporation 32 aureogen Biosciences, Inc. 33 sealife Pharma Gmbh 34 panacela Labs, Inc. 35 Candidiasis - Pipeline Review, H1 2014
  2. 2. biomar Microbial Technologies 36 candidiasis Therapeutics Assessment 37 assessment By Monotherapy Products 37 assessment By Target 38 assessment By Mechanism Of Action 41 assessment By Route Of Administration 44 assessment By Molecule Type 46 drug Profiles 48 posaconazole - Drug Profile 48 product Description 48 mechanism Of Action 48 r&d Progress 48 isavuconazonium - Drug Profile 49 product Description 49 mechanism Of Action 49 r&d Progress 49 pac-113 - Drug Profile 51 product Description 51 mechanism Of Action 51 r&d Progress 51 las-41003 - Drug Profile 53 product Description 53 mechanism Of Action 53 r&d Progress 53 ndv-3 Vaccine - Drug Profile 54 product Description 54 mechanism Of Action 54 r&d Progress 54 sq-109 - Drug Profile 56 product Description 56 mechanism Of Action 56 r&d Progress 56 pmx-30016 - Drug Profile 58 product Description 58 mechanism Of Action 58 r&d Progress 58 amphotericin B - Drug Profile 59 product Description 59 mechanism Of Action 59 r&d Progress 59 e-1210 - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 slp-0901 - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 d11-2040 - Drug Profile 62 product Description 62 mechanism Of Action 62 r&d Progress 62 xenomycin - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 augc-15 - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 compound-18545 - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 compound-9403 - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 Candidiasis - Pipeline Review, H1 2014
  3. 3. pmx-1502 - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 pmx-519 - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 candida Vaccine - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 pmx-1408 - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 e-1211 - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 slp-1002 - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 slp-0907 - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 drugs For Fungal Infections - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 small Molecules For Candidiasis - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 compound-14844 - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 program For Women Health - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 pmx-70004 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 pmx-1570 - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 pmx-1576 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 pmx-1591 - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 pmx-1625 - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 small Molecules For Aspergillosis And Candidiasis - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 Candidiasis - Pipeline Review, H1 2014
  4. 4. small Molecules For Candidiasis - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 drugs For Fungal Infections - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 pac-113 - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 candidiasis Recent Pipeline Updates 89 candidiasis Dormant Projects 99 candidiasis Discontinued Products 100 candidiasis Product Development Milestones 101 featured News & Press Releases 101 mar 14, 2014: Fda Approves Mercks Noxafil (posaconazole) Injection (18 Mg/ml) For Intravenous Use 101 nov 18, 2013: Cellceutix Identifies Pmx-1408 As Treatment Gram-negative And Candida Fungal Infections 102 nov 18, 2013: Cellceutix Identifies Drug Candidate For Candida Fungal Infections 102 nov 18, 2013: Mercks New Drug Application For An Investigational Intravenous (iv) Formulation Of Noxafil (posaconazole) Receives Fda Priority Review 103 sep 13, 2013: Basilea Reports Presentation Of Posters At Icaac On Investigational Anti-infective Isavuconazole 105 jul 17, 2013: Basilea Provides Update On Isavuconazole Phase 3 Program 107 jun 24, 2013: Fda Approves Pediatric Indication For Astellas's Mycamine For Injection 107 apr 29, 2013: Basilea Pharma Presents Data On Anti-fungal Drug Candidate Isavuconazole At Eccmid 2013 108 apr 10, 2013: Merck Announces Fda Acceptance Of Nda For Investigational Tablet Formulation Of Antifungal Noxafil 109 dec 13, 2012: Novadigm Announce Publication Of Positive Phase I Study Data Of Ndv-3 Vaccine For Candida And Staph Infections In Vaccine Journal 110 appendix 111 methodology 111 coverage 111 secondary Research 111 primary Research 111 expert Panel Validation 111 contact Us 112 disclaimer 112 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Candidiasis - Pipeline Review, H1 2014

×